Nanommune, Velox to offer microarray testing, consulting for COVID-19

2020 07 02 23 31 0378 Handshake Meeting 400

Medical biotechnology company Nanommune and clinical diagnostics company Velox Biosystems have partnered to offer rapid laboratory testing and consulting services.

The partnership aims to increase the adoption of high-plex microarray platforms among clinicians, laboratories, and researchers who want to use microarray technology for COVID-19 diagnostics but lack the experience and capabilities to perform high-throughput testing.

Nanommune and Velox will leverage their diagnostic testing experience to provide end-to-end testing and consulting services for microarray antibody and antigen assays. The companies are also working closely together to launch a COVID-19 immune profiling service and other products based on the microarray technology, according to Velox Chief Executive Officer Byron Shen.

Page 1 of 7
Next Page